PER-096-08已完成未知
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 个研究点目标入组 0 人开始时间: 2009年1月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 0（—）
- 性别
- All
入选标准
- •Histologically confirmed metastatic or unresectable renal cell carcinoma; disease must be conventional clear cell carcinoma or have a component of clear cell carcinoma
- •Patient must have measurable lesions according to the Response Evaluation Criteria In Solid Tumors (RECIST); baseline measurements must be performed =< 4 weeks prior to randomization
- •Patient must have evidence of progressive disease following treatment with a tyrosine kinase inhibitor (TKI) as assessed by the site investigator on the basis of computed tomography (CT) scans and other appropriate clinical documentation
- •Patient must have received at least one prior treatment with a VEGF receptor tyrosine kinase inhibitor for at least 12 weeks; prior treatment with either temsirolimus or everolimus is allowed; prior immunotherapy is limited to cytokine therapy with interleukin 2 and interferon alpha only
- •Previous radiotherapy (RT) is permissible provided the measurable disease is outside the RT port; RT must be completed >= 3 weeks prior to randomization
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Patient must have recovered from any toxic effects of prior radiotherapy or surgical procedures within 4 weeks prior to randomization
- •Adequate organ function as defined in the protocol
- •For women of childbearing potential, a negative serum pregnancy test is required within 1 week prior to randomization
- •Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception while on this study, and for 6 months after the completion of the study; if a woman becomes pregnant while she is on this study or within 6 months after the last dose of protocol therapy, she must inform her treating physician immediately; if a man impregnates a woman while he is on this study or within 6 months after the last dose of protocol therapy, he must inform his treating physician immediately
- •Patients who have had basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast, or lobular carcinoma in situ of the breast within the past five years are eligible only if treated with curative intent; patients with other malignancies are eligible only if they have been continuously disease-free for > 5 years prior to the time of randomization
排除标准
- •True papillary, sarcomatoid features without any clear cell component, chromophobe, oncocytoma, collecting duct tumors and transitional cell carcinoma are not eligible
- •Prior immunotherapy other than cytokine therapy with interleukin 2 and interferon alpha
- •Prior treatment with bevacizumab
- •Prior cellular therapy, vaccine, hormonal or chemotherapy for renal cell carcinoma; prior therapy for other cancers is allowable if therapy ended at least 5 years prior to enrollment
- •History of metastatic central nervous system (CNS) disease
- •Pregnant or breastfeeding
- •Myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack within 24 weeks prior to randomization
- •Prior pulmonary embolism, deep vein thrombosis, or other thromboembolic event
- •History of uncontrolled or labile hypertension, with or without antihypertensive drug treatment, within 12 weeks prior to drug administration; this is defined as blood pressure > 150/100 mm Hg or systolic blood pressure > 180 mm Hg on at least 2 repeated determinations on separate days
- •Active infection, evidence of bleeding or intratumoral bleeding, or underlying bleeding disorder
- •History of hypersensitivity to any Trap agents or recombinant proteins
- •Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy
研究者
相似试验
尚未招募
2 期
A randomised phase 2 study of carboplatin with oral vinorelbine followed by maintenance therapy with oral vinorelbine or erlotinib in elderly patients with metastatic non-small cell lung cancer.on Small Cell Lung CancerNon Small Cell Lung CancerCancer - Lung - Non small cellACTRN12612000473864Southern Health100
尚未招募
2 期
A clinical trial to check the efficacy and safety of MEDI-546 (Study drug) in subjects with Systemic Lupus ErythematosusCTRI/2012/12/003190MedImmune LLC a member of the AstraZeneca Group of300
进行中（未招募）
1 期
ASystemic Lupus ErythematosusEUCTR2011-004296-36-BGMedImmune, LLC,300
进行中（未招募）
不适用
A Study to evaluate the efficacy and safety of MEDI-546 compared toplacebo in subjects with Systemic Lupus ErythematosusSystemic Lupus ErythematosusEUCTR2011-004296-36-HUMedImmune, LLC,300
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of MEDI-546 compared to placebo in subjects with Systemic Lupus ErythematosusMedDRA version: 17.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2011-004296-36-CZMedImmune, LLC,300